Effect of preceding drug therapy on the renal and cardiovascular outcomes of combined sodium-glucose cotransporter-2 inhibitor and glucagon-like peptide-1 receptor agonist treatment in patients with type 2 diabetes and chronic kidney disease.
null nullShunichiro TsukamotoKazuo KobayashiMasao ToyodaAtsuhito ToneDaiji KawanamiDaisuke SuzukiDaisuke TsuriyaHideo MachimuraHidetoshi ShimuraHiromichi WakuiHiroshi TakedaHisashi YokomizoKei TakeshitaKeiichi ChinKeizo KanasakiMasaaki MiyauchiMasuo SaburiMiwa MoritaMiwako YomotaMoritsugu KimuraNobuo HatoriShinichi NakajimaShun ItoTakashi MurataTakaya MatsushitaTakayuki FurukiTakuya HashimotoTomoya UmezonoYoshimi MutaYuichi TakashiKouichi TamuraPublished in: Diabetes, obesity & metabolism (2024)
Although the renal composite outcome did not differ between the two groups, the win ratio of the GLP-1RA-first group versus the SGLT2 inhibitor-first group was significant. These results suggest that, in GLP-1RA and SGLT2 inhibitor combination therapy, the addition of an SGLT2 inhibitor to baseline GLP-1RA treatment may lead to more favourable renal outcomes.